Congenital bilateral agenesis of vas deferens, usually called CBAVD, means a man is born without both vas deferens. The vas deferens are the two tubes that carry sperm from the epididymis toward the urethra so sperm can mix with semen. In CBAVD, the testes often make sperm normally, but the sperm cannot travel out in the usual way. Because of this, CBAVD is a cause of obstructive azoospermia, which means sperm production may be present but sperm are blocked from reaching the semen. It is a recognized cause of male infertility and is often found when a couple cannot conceive. Sexual desire, erection, and orgasm are usually normal.
Congenital bilateral agenesis of vas deferens, also called CBAVD or congenital bilateral absence of the vas deferens, is a birth condition in which both sperm-carrying tubes do not form normally before birth. The testicles often still make sperm, but the sperm cannot travel into the semen, so the semen usually has very low volume and no sperm seen on routine testing. This means the main problem is usually obstructive infertility, not complete failure of sperm production. CBAVD is strongly linked with changes in the CFTR gene, and some people have it as a mild or isolated form of cystic-fibrosis-related disease.
CBAVD can happen by itself, or it can be part of the cystic fibrosis spectrum. Many affected men do not have full classic cystic fibrosis, but many carry changes in the CFTR gene. A smaller group have changes in ADGRG2, especially when CFTR testing is negative. Some men also have related urinary tract or kidney differences, so the condition is not only about fertility; it can also point to a developmental problem that happened before birth.
Another Names
Other names used for this condition include congenital bilateral absence of the vas deferens, bilateral congenital absence of the vas deferens, bilateral aplasia of the vas deferens, CAVD when speaking more generally, and male infertility due to obstructive azoospermia from absent vasa deferentia. In medical writing, CBAVD is the most common short name.
Types
Type 1: Isolated CBAVD. This means both vas deferens are absent, but the man has no obvious classic cystic fibrosis symptoms. This is the most common clinical pattern seen in fertility clinics.
Type 2: CBAVD linked to cystic fibrosis spectrum disease. In this type, CBAVD is connected to CFTR-related disease. Some men have full cystic fibrosis, while others have mild breathing, sinus, or digestive problems only.
Type 3: CBAVD with other Wolffian duct or seminal tract anomalies. In this type, the absent vas deferens is seen together with changes in the epididymis, seminal vesicles, or ejaculatory system, because these structures develop from related embryologic tissues.
Type 4: CBAVD with urinary tract anomalies. Some men also have kidney or ureter differences, such as unilateral renal agenesis. This matters because renal imaging may find an associated birth difference that was never noticed before.
Causes
1. CFTR gene mutation. This is the best-known cause. CFTR helps control salt and water movement in body tissues. When it does not work normally, the male reproductive tract may not form in the usual way before birth. More than half of affected men have CFTR variants.
2. Two mild CFTR variants together. Some men do not have classic cystic fibrosis, but they inherit two milder CFTR changes. These milder combinations may mainly affect the reproductive tract instead of causing full-body disease.
3. CFTR 5T variant in intron 8. The 5T tract is a well-known CFTR-related risk factor for CBAVD. It can reduce correct gene processing, which lowers normal CFTR function.
4. TG12 or TG13 repeat next to the 5T variant. These nearby repeats can make the 5T effect stronger. So the gene may work even less well, and the chance of CBAVD becomes higher.
5. Severe CFTR mutation on one side and mild CFTR mutation on the other side. This mixed pattern is another recognized genetic explanation. It may cause genital tract disease without full classic cystic fibrosis.
6. ADGRG2 mutation. ADGRG2 is another gene linked to CBAVD, especially in men without CFTR findings. Because this gene is on the X chromosome, the inheritance pattern is different from CFTR-related cases.
7. X-linked ADGRG2 loss-of-function disease. Some ADGRG2 variants clearly stop the protein from working. In these men, the sperm passage system may become abnormal during development or become blocked very early.
8. Abnormal Wolffian duct development in the embryo. The vas deferens develops from the mesonephric or Wolffian duct. If this duct does not develop correctly very early in fetal life, the vas deferens may be absent on both sides.
9. Failure of normal differentiation of the vas deferens. Sometimes the basic problem is not complete absence of the early duct, but failure of that tissue to become a mature vas deferens. The result is the same: sperm has no normal transport tube.
10. Developmental atresia of the vas deferens. In some descriptions, the vas is present only as a tiny remnant or an incomplete structure. This is still grouped with congenital absence because function is lost.
11. CFTR-related genital form of cystic fibrosis. Some men have a genital-only or genital-predominant form of CFTR disease. Their main or only major problem is infertility from CBAVD.
12. Partial embryologic defect affecting vas deferens and seminal vesicles together. Because these organs develop from related structures, a shared early defect can affect both. This helps explain why seminal vesicle changes are common in CBAVD.
13. Developmental defect associated with epididymal anomalies. The epididymis and vas deferens are closely connected. Some men with CBAVD also have epididymal malformations, showing a wider congenital tract disorder.
14. Developmental defect associated with ejaculatory tract abnormalities. In some men, the absent vas deferens appears with distal seminal tract changes. This supports the idea of a broad congenital obstructive disorder rather than one isolated missing tube.
15. Renal-associated mesonephric duct maldevelopment. The kidney and vas deferens both relate to early mesonephric development. If this early system develops abnormally, CBAVD can appear together with renal agenesis or other urinary anomalies.
16. Non-CF genetic disease not yet fully identified. Not every patient has CFTR or ADGRG2 mutations. This means there are likely more genes still being studied.
17. Ethnic-specific genetic variant patterns. Different populations show different CFTR mutation patterns and frequencies. This does not create the disease by itself, but it changes which inherited causes are more common in different groups.
18. Family-transmitted recessive reproductive tract malformation. In many CFTR-related cases, the disease happens because harmful gene changes are inherited from both parents. The man is born with the condition, even if no one knew it in childhood.
19. Family-transmitted X-linked reproductive tract disorder. In ADGRG2-related cases, the disease may run through the mother’s side because the gene is on the X chromosome. This is important for family counseling.
20. Congenital malformation of sperm transport pathways present from fetal life. In simple words, the final common cause is that the sperm-carrying tubes never formed normally before birth. Whatever the exact gene or developmental mistake, the end result is the same obstructive infertility pattern.
Symptoms
1. Infertility. This is the most common way CBAVD is found. Many men feel healthy and only learn about the problem after trying to have a child.
2. Azoospermia. Azoospermia means no sperm are seen in the semen. In CBAVD, this usually happens because sperm cannot travel out, not because the testes fail to make sperm.
3. Very low semen volume. The ejaculate is often small, commonly under about 1 mL, because seminal tract abnormalities are common.
4. Acidic semen. The semen pH is often low. This lab clue helps doctors think about CBAVD or other distal obstructive causes.
5. Little or no fructose in semen. Fructose usually comes from the seminal vesicles. Low or absent fructose supports the idea of seminal tract abnormality.
6. Normal sexual desire. CBAVD usually does not reduce libido. Most men have normal interest in sex.
7. Normal erection. Erectile function is usually normal because the condition mainly affects sperm transport, not erection pathways.
8. Normal orgasm and ejaculation feeling. A man can still orgasm and ejaculate fluid, but the semen usually has no sperm.
9. Sometimes mild breathing symptoms. Some men have chronic sinus or lung symptoms if their CBAVD is part of a mild CFTR-related disorder.
10. Sometimes mild digestive symptoms. A smaller group may have digestive complaints related to CFTR dysfunction, even without full classic cystic fibrosis.
11. No pain in many cases. CBAVD often causes no scrotal pain, which is why it can stay hidden until fertility testing starts.
12. Partner not becoming pregnant. In real life, this is often the first practical sign noticed by the couple.
13. Sometimes lower sperm count instead of complete absence. While azoospermia is classic, some sources note oligospermia can also be seen in certain related or partial forms.
14. Sometimes associated urinary tract finding discovered later. A man may have no urinary symptom, but a kidney anomaly may be discovered during workup. Even silent findings matter because they change counseling and follow-up.
15. Emotional stress from unexplained infertility. This is not the biological defect itself, but it is a common real-life effect when the diagnosis is made. Infertility evaluation guidelines recognize the importance of counseling and full partner care.
Diagnostic Tests
1. Fertility history. The doctor asks how long pregnancy has been attempted, whether there were prior pregnancies, and whether there are signs of cystic fibrosis or past scrotal problems. This helps place CBAVD inside the larger infertility picture.
2. General physical examination. A basic exam looks at body development, signs of hormonal problems, chest findings, and any clue of syndromic disease. CBAVD often has otherwise normal male development.
3. Scrotal palpation of the vas deferens. This is one of the most important bedside tests. An experienced doctor gently feels along the spermatic cord to check whether each vas deferens is present. In CBAVD, both are usually not palpable.
4. Testicular size assessment. The testes are often normal or only slightly small. Normal-sized testes support an obstructive cause rather than severe testicular failure.
5. Epididymis examination. The epididymis may feel abnormal, absent in part, or enlarged depending on the anatomy. This helps the doctor understand whether there are wider tract anomalies.
6. Digital rectal examination when needed. In selected men, the doctor may examine the prostate and nearby structures to look for other obstructive causes. This is not specific for CBAVD but can help with differential diagnosis.
7. Semen analysis. This is a key lab test. It often shows azoospermia in CBAVD. Usually at least two semen analyses are done to confirm the finding.
8. Semen volume measurement. Low ejaculate volume strongly supports a distal obstructive problem such as CBAVD. It is a simple but very useful clue.
9. Semen pH test. Acidic semen helps point toward absence or dysfunction of structures that normally add alkaline fluid. This is a classic laboratory feature in CBAVD.
10. Seminal fructose test. Low or absent fructose suggests seminal vesicle involvement or distal obstruction. In CBAVD this finding often fits the whole pattern.
11. Serum FSH. Follicle-stimulating hormone is often normal in CBAVD because sperm production in the testes is often preserved. It helps separate obstruction from primary testicular failure.
12. Serum LH and testosterone. These hormone tests are not diagnostic by themselves, but they help rule out endocrine causes of infertility. They are often normal in isolated CBAVD.
13. CFTR genetic testing. This is strongly recommended because CFTR mutations are common in CBAVD and matter for family planning. The partner may also need testing to estimate the chance of cystic fibrosis in a child.
14. ADGRG2 genetic testing. This is especially useful when CFTR testing is negative. It can explain some X-linked cases and improves genetic counseling.
15. Genetic counseling assessment. This is part of the diagnostic workup because the test results affect future children and family members. It helps explain inheritance, carrier risk, and reproductive options.
16. Scrotal ultrasound. Ultrasound can help visualize associated epididymal and scrotal anatomy and support the clinical exam, especially when palpation is uncertain.
17. Transrectal ultrasound. This imaging test looks at the seminal vesicles and ejaculatory ducts. It helps distinguish CBAVD from ejaculatory duct obstruction and other distal causes of low-volume azoospermia.
18. Renal ultrasound. Kidney imaging is important because some men with CAVD have renal agenesis or other urinary tract anomalies. A silent kidney difference may only be found during this test.
19. MRI in selected cases. MRI is not routine for every patient, but it may be used when anatomy remains unclear after ultrasound. It gives a detailed picture of pelvic structures.
20. Testicular biopsy or sperm retrieval assessment in selected men. This is not always needed just to diagnose CBAVD, but it may be done when doctors need proof that sperm production is present or when planning assisted reproduction. In many men with CBAVD, spermatogenesis is preserved.
Non-pharmacological treatments, therapies, and supportive measures
1. Fertility specialist consultation is one of the best first steps. Its purpose is to confirm that infertility is due to a transport problem, not a hormone problem. The mechanism is careful history, physical examination, semen review, and planning for sperm retrieval or IVF-ICSI. It helps avoid wrong treatment and saves time.
2. Genetic counseling helps the patient understand why CBAVD happened and what it may mean for future children. Its purpose is risk assessment. The mechanism is discussion of CFTR and sometimes ADGRG2 testing, inheritance patterns, and reproductive options.
3. Partner genetic testing is important, especially for CFTR variants. Its purpose is to estimate the risk of cystic fibrosis or related disease in a child. The mechanism is carrier screening in both partners before IVF or ICSI.
4. Repeat semen analysis helps confirm obstructive azoospermia. Its purpose is accurate diagnosis. The mechanism is checking semen volume, pH, and sperm presence more than once because one test alone can mislead.
5. Physical examination of the vas deferens can show that the tubes are not felt in the scrotum. Its purpose is bedside diagnosis. The mechanism is direct palpation by an experienced clinician.
6. Scrotal ultrasound helps look at testicles and epididymis. Its purpose is supportive evaluation. The mechanism is imaging that checks anatomy and looks for other causes of infertility.
7. Transrectal ultrasound helps assess seminal vesicles and ejaculatory structures. Its purpose is to support the diagnosis of obstruction-related infertility. The mechanism is detailed pelvic imaging.
8. Kidney ultrasound is often advised because some people with vas deferens anomalies can also have urinary tract or kidney anomalies. Its purpose is to find associated structural problems early. The mechanism is painless abdominal imaging.
9. CF-related clinical review is useful if the person has cough, sinus disease, digestive trouble, or family history. Its purpose is to detect mild cystic fibrosis or CFTR-related disease. The mechanism is symptom review and targeted testing.
10. Sperm retrieval planning is central care. Its purpose is to obtain sperm directly from the epididymis or testicle for assisted reproduction. The mechanism is choosing the safest, most effective retrieval method before IVF-ICSI.
11. PESA means percutaneous epididymal sperm aspiration. Its purpose is to collect sperm without needing a vas deferens. The mechanism is needle aspiration from the epididymis, where sperm are often present.
12. MESA means microsurgical epididymal sperm aspiration. Its purpose is to collect high-quality sperm under direct vision. The mechanism is a minor microsurgical procedure, often used when a more controlled retrieval is preferred.
13. TESA means testicular sperm aspiration. Its purpose is sperm recovery when epididymal retrieval is not ideal. The mechanism is needle sampling from testicular tissue.
14. TESE means testicular sperm extraction. Its purpose is direct sperm retrieval from the testis. The mechanism is small tissue sampling, and in obstructive cases the retrieval rate is generally high.
15. Cryopreservation means sperm freezing. Its purpose is to avoid repeat procedures and keep sperm ready for later IVF-ICSI. The mechanism is laboratory freezing and storage after retrieval.
16. IVF with ICSI counseling is essential because ICSI is often the route to biological fatherhood in CBAVD. Its purpose is informed decision-making. The mechanism is joining one sperm with one egg in the lab after retrieval.
17. Psychologic counseling matters because infertility can cause shame, stress, and relationship strain. Its purpose is emotional support. The mechanism is guided coping, communication work, and decision support.
18. Lifestyle optimization such as stopping smoking, limiting alcohol, sleeping well, and keeping a healthy weight does not cure CBAVD, but it may support general reproductive and surgical health. The mechanism is reducing oxidative and metabolic stress.
19. Avoiding testosterone abuse is very important. Its purpose is to protect sperm production. The mechanism is simple: outside testosterone can suppress the body’s own pituitary signals and lower spermatogenesis.
20. Family-building alternatives such as donor sperm, donor embryo, adoption, or choosing a child-free life are valid evidence-based options. Their purpose is to reduce pressure and widen choice. The mechanism is not medical cure, but realistic reproductive planning.
Drug treatments:
For CBAVD itself, no FDA-approved drug restores the missing vas deferens. So the medicines below are not a cure for CBAVD. They are drugs sometimes used in related fertility treatment plans, mainly during ART/IVF-ICSI, or in rare coexisting hormone disorders. That distinction is very important.
1. Follitropin alfa (GONAL-F), 2. follitropin beta (Follistim), 3. menotropins (Menopur), 4. urofollitropin-type FSH products, 5. chorionic gonadotropin/Pregnyl, 6. choriogonadotropin alfa/Ovidrel, 7. ganirelix, 8. cetrorelix, 9. progesterone vaginal insert, 10. progesterone gel, 11. progesterone vaginal system, 12. progesterone injection are fertility-program medicines used around egg stimulation, ovulation triggering, or luteal support in the female partner during IVF or ICSI. Their purpose is to help create and support embryos after sperm retrieval from the male with CBAVD. Their mechanisms differ: FSH products stimulate follicles; hCG products trigger final maturation; GnRH antagonists prevent premature LH surge; progesterone supports implantation. Important side effects can include ovarian hyperstimulation syndrome, injection reactions, headache, abdominal pain, bloating, and multiple pregnancy risk in ovarian stimulation cycles.
13. hCG in selected male hypogonadotropic hypogonadism, 14. hCG plus FSH in selected male endocrine infertility, 15. GnRH-based endocrine therapy in rare specialist settings, 16. antibiotics only when infection is separately proven, 17. pain medicines after sperm retrieval, 18. anesthesia medicines during procedures, 19. stool softeners after surgery if needed, 20. anti-inflammatory supportive medicines when prescribed may appear in care plans around infertility treatment, but they are not disease-specific CBAVD medicines. In true isolated CBAVD, hormones are often normal and these medicines are often unnecessary.
Dietary molecular supplements
Supplements can be discussed only as general fertility-supportive options, not as a cure. Evidence for male subfertility supplements is mixed, and evidence specifically for CBAVD is weak because the main problem is a missing tube, not a vitamin deficiency.
1. Zinc, 2. folate/folic acid, 3. vitamin C, 4. vitamin E, 5. coenzyme Q10, 6. L-carnitine, 7. selenium, 8. omega-3 fatty acids, 9. vitamin D, 10. N-acetylcysteine are sometimes used in fertility clinics to support antioxidant balance, membrane stability, mitochondrial energy, or sperm function. Their purpose is mainly to support sperm quality in some infertile men, but they do not create a vas deferens. Mechanistically, most work through antioxidant or cellular support pathways. In practice, doses vary by product and clinic, and high doses can cause side effects or interact with other treatment. The safest rule is to use supplements only after a fertility specialist reviews the case.
Immunity booster, regenerative, or stem-cell drugs
At present, there is no established immune booster, regenerative drug, or stem-cell medicine that is proven to rebuild the absent vas deferens in CBAVD in routine clinical care. This is one area where honest medicine matters more than a long list. Selling “stem-cell cures” for CBAVD would not be evidence-based. The best current care remains diagnosis, genetic counseling, sperm retrieval, and IVF-ICSI.
Surgeries or procedures
1. PESA, 2. MESA, 3. TESA, 4. TESE, and 5. IVF-ICSI laboratory fertilization after retrieval are the main procedure-based treatments linked to CBAVD. They are done to obtain sperm and then create a pregnancy pathway despite the absent vas deferens. In contrast, microsurgical reconstruction is usually not the standard answer for true CBAVD because the tube is congenitally missing.
Prevention points
Because CBAVD is congenital, there is no guaranteed way to prevent the condition in someone already conceived. Prevention mainly means genetic risk reduction for future pregnancies: 1) genetic counseling, 2) partner CFTR testing, 3) informed IVF planning, 4) embryo-related genetic discussion where appropriate, 5) family history review, 6) avoiding unproven fertility scams, 7) early infertility workup, 8) protecting general sperm health, 9) avoiding testosterone misuse, and 10) early specialist referral instead of delay.
When to see a doctor
You should see a doctor if you have infertility for 12 months, very low semen volume, azoospermia on a semen test, a missing vas deferens on examination, a family history of cystic fibrosis, repeated sinus or lung symptoms, or kidney/urinary tract anomalies. See urgent care quickly if there is severe scrotal pain, fever, swelling, or breathing problems. The best specialists are usually a male infertility urologist and a reproductive endocrinology/IVF team.
What to eat and what to avoid
Helpful food choices are: 1. fish, 2. eggs, 3. beans, 4. nuts, 5. fruits, 6. vegetables, 7. whole grains, 8. yogurt, 9. olive oil, 10. enough water. Foods and habits to limit are smoking, heavy alcohol, ultra-processed food, excess trans fat, and uncontrolled obesity-promoting diets. These steps support overall health and possibly sperm quality, but again they do not fix the missing vas deferens.
FAQs
1. Is CBAVD the same as cystic fibrosis? No. Some people with CBAVD have CFTR-related disease, but not all have classic cystic fibrosis.
2. Can men with CBAVD make sperm? Often yes. The main problem is transport, not sperm production.
3. Why is semen volume often low? Because related structures such as the seminal vesicles may also be abnormal, so semen fluid can be reduced.
4. Can CBAVD be cured with tablets? No proven tablet or injection can regrow the missing vas deferens.
5. Can a man with CBAVD have a biological child? Yes, many can through sperm retrieval and IVF-ICSI.
6. Is surgery always needed? Usually a sperm retrieval procedure is needed if biological fatherhood is desired.
7. Should the female partner be tested too? Yes, partner genetic testing is important, especially for CFTR variants.
8. Are kidney problems linked with CBAVD? They can be, so renal imaging is often considered.
9. Does testosterone help fertility here? Not usually, and non-prescribed testosterone can worsen sperm production.
10. Do supplements cure CBAVD? No. They may support general fertility health at best, but they do not replace the absent tube.
11. Is IVF always necessary? For most couples seeking a biological child, IVF with ICSI is the usual path.
12. Is CBAVD rare? Yes. It is an uncommon but important cause of obstructive azoospermia and male infertility.
13. Can CBAVD affect health outside fertility? Sometimes yes, especially if it is part of a CFTR-related condition.
14. Is stem-cell treatment available now? Not as a proven standard treatment for rebuilding the vas deferens.
15. What is the most important next step after diagnosis? Meet a male infertility specialist and get genetic counseling before fertility treatment.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 10, 2025.
